Company Overview and News
Retail sales registered a stable increase last month, posting its best rise since last November. Upbeat sentiment over consumer spending boosted retail sales and is expected to continue to benefit retailers in the coming months. Stable job growth, better consumer confidence and a positive impact of tax cuts are expected to boost consumer spending and drive retail sales in the near future.
WASHINGTON (Reuters) - Two black men who were arrested at a Starbucks Corp cafe in Philadelphia while waiting for a friend said on Thursday they hoped the widely publicized incident would lead to changes in U.S. racial attitudes.
In my last Monday Musings post, I shared 5 tips to help have a successful earnings season as an investor. Now, I wanted to share my specific watchlist that I have researched thoroughly and am anxiously waiting to possibly add to my portfolio.
LOS ANGELES (Reuters) - Starbucks Corp (SBUX.O) turned to long-time leader Howard Schultz on Wednesday to make the case that the U.S. coffee chain accused of racial profiling is committed to offering a “safe space” to customers despite the arrest of two black men in one of its Philadelphia cafes.
Starbucks Corp turned to long-time leader Howard Schultz on Wednesday to make the case that the U.S. coffee chain accused of racial profiling is committed to offering a "safe space" to customers despite the arrest of two black men in one of its Philadelphia cafes.
Starbucks Corporation (NASDAQ:SBUX) CEO Kevin Johnson is currently facing his biggest challenge since replacing Howard Schultz as the company’s chief executive a year ago.
When a company that prides itself on its social consciousness does something stupid, the genie escapes and there’s no getting it back in the magic lantern. That’s what happened last Thursday at Starbucks Corp. (NASDAQ: SBUX).
Starbucks (SBUX - Free Report) has announced its plan to close more than 8,000 company-owned U.S. stores for several hours next month, to conduct anti-bias training for nearly 175,000 workers. This move of the coffee-chain giant is mainly aimed to address the recent uproar over the arrest of two black men at one of its stores in Philadelphia. The company’s CEO Kevin Johnson called the incident "reprehensible" and apologized to the two men face-to-face.
April 18 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
The store closures Starbucks Inc. announced Tuesday for racial-bias employee training will cost the company about $12 million in lost revenue, according to MarketWatch calculations.
Philadelphia police released the 9-1-1 call and officer transmissions related to an incident with the arrest of two black men at a Starbucks on April 12 that has drawn national attention. A viral video showed two men being arrested after the store’s manager called police as they were sitting waiting for a third man without ordering anything. The store has been the scene of protests since the video surfaced.
STARBUCKS says it will close its more than 8000 U.S. stores for several hours next month to conduct racial-bias training to its nearly 175,000 workers. The announcement comes after two black men were arrested in a Philadelphia Starbucks store, sparking protests and calls for a boycott on social media. Starbucks Corp. says the stores will be closed on the afternoon on May 29. Its corporate offices will also be closed at that time.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET